Johnson & Johnson JNJ

$263.81 -3.80 (-1.42%)

Valuation

Market cap
644,912,768,000
Revenue TTM
$94,193,000,000
Net income TTM
$26,804,000,000
PE ratio
24.20
Forward PE
23.19
Profit margin
28.46%
Debt to equity
0.44

Trading

Volume
5,309,100
Avg volume
6,964,168
Day's range
$262.40 – $266.03
Shares out
2,409,898,000
Stochastic %K
76%
Beta
0.21
Analysts
Strong Sell
Price target
$282.24

Price

Company profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular...

Show more

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
732 524 0400
Website
https://www.jnj.com
Address
One Johnson & Johnson Plaza, New Brunswick, United States

Latest news

Stocktwits

focafoca99 Oct 24, 1:05 PM
$JNJ reported a 62% lower risk of recurrence or death with apalutamide plus ADT versus surgery alone in prostate cancer. https://www.rapidticker.com/news/jnj-johnson-johnson-announces-erleada-apalutamide-7d45cd
1 replies
flychicken1991 Oct 24, 1:00 PM
$JNJ Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk prostate cancer. Impact: Positive (84%). shares could receive modest upward support as stronger evidence for an additional ERLEADA indication increases the perceived value of future drug sales; the announcement establishes no immediate earnings increase. Source and what to watch next: https://nimpact.tech/newsimpact/news/ae16257df6eb8ecb/jnj-johnson-johnson-announces-erleada-apalutamide-treatment-before-and-a?utm_source=stocktwits&utm_medium=story_url
0 replies
Rayvio_News_Filter Oct 24, 12:56 PM
$JNJ 🏥 Johnson & Johnson announced Phase 3 PROTEUS substudy results showing perioperative apalutamide plus ADT for six months before and after surgery reduced risk of recurrence or death by 62% versus surgery alone in high-risk prostate cancer, with 51% lower estimated risk of metastasis or death and twice as many patients free from subsequent treatment at three years. Curated for market relevance
0 replies
TopOptionAlert Oct 24, 11:19 AM
$JNJ NOV20 270C · still actionable Zone: $261.96 to $265.66 Invalidation: close under $259.04 Objectives: $269.67, then $281.07 The math: up 2.2% to the first objective and 6.5% to the second, against 1.8% risk on the invalidation, better than 3 to 1 to the second. Dear friend, picture a shop that jumped from 258 dollars on Wednesday to 270 dollars on Thursday, then eased back on Friday to 263 dollars and 81 cents. This is a swing, and the idea is simple. You are betting Friday was a breather, not a reversal, because price holds above the 259 dollar floor from Thursday, with room back toward the Thursday high first and then toward the high for the year near 281 dollars, while a close under that floor says the jump has faded and you step aside. The next company event is not until December 8, so this window is about price, not a report. P.S. Watch 266 dollars and 2 cents, the high printed on Friday, because a move over it shows buyers taking the ground back.
0 replies
thatsolardude365 Oct 24, 9:22 AM
$JNJ: MDL 2738 is now fighting over expert science. A Jan. 20, 2026 Special Master report tackled Daubert challenges in the talc cases before Judge Shipp. No settlement, nothing to claim. Open Class Actions.
0 replies
LewisIntegrated Oct 23, 6:11 PM
If you’ve ever wanted to catch a short squeeze early instead of watching it rip after the fact, this group is built for that. Sharing momentum, setups, and what we’re watching as it develops, not when it’s already gone. Click link and join for Free ⭐ $JNJ ))
0 replies
graywolf Oct 23, 5:28 PM
$JNJ $SLS Both are holding well despite market weakness. Make it happen!
0 replies
55X_ROI_Q1_2026 Oct 23, 4:44 PM
$SLS $BMY $JNJ
0 replies